
Rigenerand
Develops and manufactures cGMP-grade systems and products for cell- and gene-therapy applications using 3D culture and clean-room facilities.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | Acquisition | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | (58 %) | 412 % | 362 % | 1628 % | 126 % | 25 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (3770 %) | (12958 %) | (5217 %) | (969 %) | - | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (5205 %) | (19839 %) | (7813 %) | (1655 %) | (213 %) | 23 % | 3 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Rigenerand operates in the advanced medicine sector, focusing on the development and production of cGMP (current Good Manufacturing Practice) products for cell and gene therapy. The company also specializes in creating tailored 3D culture biomedical devices used for both diagnostic and therapeutic applications. Rigenerand serves clients in the pharmaceutical and biotechnology industries, providing solutions that enhance drug testing, gene therapy, and immuno-oncology research. The company’s business model revolves around the sale of its proprietary products and services, which are designed to meet stringent regulatory standards and improve patient outcomes. Rigenerand generates revenue through the commercialization of its innovative 3D bioreactor systems and extracellular vesicle exosomes, which are essential for advanced therapeutic applications. The company is ISO 9001:2015 certified by TUV SUD, ensuring high-quality standards in its operations.
Keywords: cGMP, cell therapy, gene therapy, 3D culture, biomedical devices, diagnostics, therapeutics, bioreactor, exosomes, immuno-oncology.